Axonis Therapeutics
Boston
About Axonis Therapeutics
Axonis Therapeutics is a neuro-focused biotechnology company developing medicines targeting KCC2, the critical mediator of inhibition within the brain, by translating breakthrough discoveries from Boston Children’s Hospital, Harvard, and Laval University. It develops a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine to improve the lives of people suffering from neurological disorders by fine-tuning inhibition to treat conditions such as epilepsy, pain, and other central nervous system pathologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $129.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2024)
- Website: axonis.us
- Phone: (617) 221-5364
Industries & Categories
Biotechnology, Life Science, Medical, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/axonis-therapeutics-44822 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.